NCT04278131RecruitingPhase 1/2
BS01 in Patients With Retinitis Pigmentosa
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 13 Feb 2020
- Start date
- 6 Feb 2020
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Bionic Sight LLC
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT04278131
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 20
- From 6 Feb 2020 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior receipt of any AAV gene therapy product
Other
- Large amplitude nystagmus
Who the study is looking for
- Confirmed diagnosis of retinitis pigmentosa
- At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New Jersey Retina Coordinator of this site? Confirm its status | Teaneck | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.